预约演示
更新于：2026-04-03
Brinzolamide
布林佐胺
更新于：2026-04-03
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H21N3O5S3 |
InChIKeyHCRKCZRJWPKOAR-JTQLQIEISA-N |
CAS号138890-62-7 |
关联
53
项与 布林佐胺 相关的临床试验CTRI/2024/07/071413
A Randomized, Double-masked, Active Controlled, Parallel Group, Two-arm, Multi Center,in-vivo Bioequivalence Study with Clinical Endpoint Comparing Brinzolamide OphthalmicSuspension, USP 1 Percent of Riconpharma LLC, USA to AZOPT® (Brinzolamide OphthalmicSuspension) 1 Percent of Novartis Pharmaceuticals Corporation, USA in subjects with Chronic OpenAngle Glaucoma or Ocular Hypertension in both eyes - Nil
CTRI/2023/06/054478
A multicenter, randomized, assessor-blinded, active controlled, parallel group, two arm, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml + Brimonidine tartrate 2 mg/ml eye drops suspension (AZAD Pharma AG, Switzerland) and Simbrinza® (Brinzolamide 10 mg/ml + Brimonidine tartrate 2 mg/ml) eye drops suspension (Novartis Europharm Limited, Ireland ) in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
EUCTR2022-002524-12-BG
A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml eye drops suspension (Brinzolamide 10mg/ml Eye Drops Suspension Preservative Free) as a test product versus AZOPT® 10 mg/ml eye drops suspension as reference product in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension
100 项与 布林佐胺 相关的临床结果
登录后查看更多信息
100 项与 布林佐胺 相关的转化医学
登录后查看更多信息
100 项与 布林佐胺 相关的专利（医药）
登录后查看更多信息
669
项与 布林佐胺 相关的文献（医药）2026-03-01EXPERIMENTAL EYE RESEARCH
Mechanical and cellular response of lenses to acute ocular hypertension: Implications of AQP1 regulating water transport and lenses opacification
Article
作者: Zhu, Jingyi ; Luo, Linlin ; Ye, Jian ; Hu, Qiumei ; Chen, Xiao ; Luo, Qian ; Yang, Lei
The morphological, mechanical, and cellular response of lenses to acute elevation of intraocular pressure (IOP) remained largely unknown. Therefore, we carried out a comprehensive study on the changes of mouse lenses after acute elevation of IOP, and explored the underlying molecular biological mechanism. Acute ocular hypertension was induced in the eye of adult C57BL/6J mice by cannulation of the anterior chamber. Gross morphology and ultrastructure of the lenses were evaluated by the slit lamp, OCT examinations, immunofluorescence staining, immunohistochemistry, and electron microscope, and physical properties were also measured. RNA sequencing analysis was applied to detect relevant transcriptional alterations. We found that subcapsular lens opacities appeared after the IOP spike. The volume, weight, and water content were subsequently decreased. While the lens capsules and LECs attached displayed no significant structural changes after IOP elevation compared with control lenses, the subcapsular cortex was compressed and disorganized. RNA sequencing analysis showed the biological changes of lenses involve various aspects such as cell adhesion and lens fiber remodeling. Lastly, we confirmed that brinzolamide eye drop was able to reduce the AQP1 level, and improve both the transparency and the water content of the lenses after IOP elevation. In conclusion, our study updates the fundamental insight towards the biomechanical response of lenses and their correlation with cataract development, paving the way for further exploration of protection towards lenses after the IOP spike.
2026-02-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Ophthalmic-targeted brinzolamide-laden cubosomal solid lipid nano-vesicular system (Cube-SLNV): design, development, and in vitro and ex vivo characterization
Article
作者: Bhalodia, Ujash ; Gandhi, Tejal ; Patel, Ayushi ; Modi, Chetna ; Thakkar, Vaishali ; Rana, Hardik ; Dholakia, Mansi
A better functional and site-specific drug delivery system for ophthalmic disease is necessary for the treatment of glaucoma. The present study aimed to design a brinzolamide (BRZ)-loaded cubosomal solid lipid nano-vesicular system (Cube-SLNV) that accomplished advanced statistical tools. Another objective was to overcome the problem of burst release associated with Glyceryl monooleate (GMO) Cube-SLNV by incorporating Gelucire 43/01 (GC43/01). The emulsification method was used to synthesize BRZ Cube-SLNV. The Plackett-Burman design (PBD) was utilized to screen the critical material (CMAs) and process attributes (CPPs). The optimization of the Cube-SLNV was accomplished through Box-Behnken design (BBD). Multivariate tools were applied to estimate the correlation between screened CMAs and critical quality attributes (CQAs). The Cube-SLNV was characterized by size, its size distribution, stability, thermal behavior, chemical interactions, BRZ release, entrapment efficiency, pH, sterility testing, and ex vivo irritation study. GMO and GC43/01 were chosen as solid lipids, whereas Poloxamer 407 (PLX) was a stabilizer for Cube-SLNV in preliminary trials. PBD-the Pareto chart suggested the significant influence of the amount of GMO, GC43/01, and PLX on the performance of Cube-SLNV, so chosen as CMAs for further optimization. BBD identified a crucial relationship between chosen CMAs and CQAs - Cube-SLNV size, poly-dispersibility index (PDI), and BRZ release. The optimized Cube-SLNV size was determined to be 101.2 nm, with a zeta potential of - 34.6 mV, a PDI of 0.253, and more than 90% entrapment efficiency. Cube-SLNV can release more than 90% BRZ within 8 h. DSC and FTIR confirmed the formation of Cube-SLNV-loaded BRZ. HATCAM study revealed that the formulation has no irritancy. The controlled release behavior from optimized BRZ with higher entrapment efficiency was observed. Cube-SLNV was developed with the amalgamation of PBD for screening and BBD for correlating CMAs and CQAs. This novel delivery system is a revitalized formulation that promises to give a potential molecule a new lease of life.
2025-11-01VETERINARY OPHTHALMOLOGY
Retrospective Assessment of Carbonic Anhydrase Inhibitors in Topical or Episcleral Implant Form for the Treatment of Equine Glaucoma
Article
作者: Gilger, Brian ; Tucker‐Retter, Emily K. ; Yamagata, Maya ; Oh, Annie
ABSTRACT:
Objective:
To assess whether topical carbonic anhydrase inhibitors (CAIs) with or without episcleral brinzolamide implants control intraocular pressure (IOP) in horses with glaucoma.
Animals Studied:
12 client‐owned horses diagnosed with glaucoma.
Procedures:
Medical records of horses treated with topical CAIs for ≥ 14 days, with a subset receiving episcleral brinzolamide implants, were reviewed. Diagnosis, signalment, concurrent ocular disease, medications, IOP, visual status, and additional procedures were recorded. Treatment failure was defined as horses with IOP > 30 mmHg resulting in phthisis bulbi or requiring a procedure or enucleation.
Results:
Secondary glaucoma was diagnosed in 8/12 (67%) eyes and primary glaucoma in 4/12 (33%) eyes. IOP was < 30 mmHg in 7/12 (58%) eyes after treatment with topical CAIs for a median of 28 days. Episcleral brinzolamide implants were placed in 7/12 eyes after a median of 58 days of medical therapy. Treatment failure occurred in 3/7 horses (43%) receiving brinzolamide implants at a median of 189 days and in 4/5 medical therapy‐only horses (80%) at a median of 51 days. While 6/12 eyes (50%) were visual at last follow‐up (median of 161 days), enucleation was the final outcome in 10/12 (83%) eyes.
Conclusions:
Topical CAIs appear to result in temporary IOP control in a subset of horses, though some horses may be refractory. Episcleral brinzolamide implants may extend IOP control in horses with glaucoma, but prognosis for vision remains guarded and further optimization is needed.
14
项与 布林佐胺 相关的新闻（医药）2026-01-30
2025-12-08
2025-08-20
100 项与 布林佐胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2002-12-10 | |
| 开角型青光眼 | 美国 | 1998-04-01 | |
| 高眼压症 | 美国 | 1998-04-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 虹膜色素剥脱综合征 | 临床阶段不明 | 美国 | 2003-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 599 | (BRIN-20-01) | 蓋鬱簾窪鹹構鹹蓋積鹽(廠鏇淵築糧網製壓顧壓) = 選願製艱選齋簾淵夢範 鑰構餘膚夢夢顧積鏇觸 (廠衊製衊願齋積廠齋製, 2.290) 更多 | - | 2024-01-18 | ||
(Azopt®) | 蓋鬱簾窪鹹構鹹蓋積鹽(廠鏇淵築糧網製壓顧壓) = 廠範憲構餘糧積選鹽繭 鑰構餘膚夢夢顧積鏇觸 (廠衊製衊願齋積廠齋製, 2.363) 更多 | ||||||
临床3期 | 495 | (Perrigo Active) | 壓製夢襯蓋築齋膚窪願(蓋繭網糧構膚蓋憲憲壓) = 鹹顧艱構餘廠獵艱網齋 鹹壓壓製網築簾網醖製 (餘鏇顧鑰鹹遞製糧廠簾, 2.713) 更多 | - | 2023-03-06 | ||
(Reference Active) | 壓製夢襯蓋築齋膚窪願(蓋繭網糧構膚蓋憲憲壓) = 壓襯願糧鑰窪簾簾憲醖 鹹壓壓製網築簾網醖製 (餘鏇顧鑰鹹遞製糧廠簾, 2.719) 更多 | ||||||
临床1/2期 | 637 | (Brinzolamide 1% Ophthalmic Suspension) | 鹹鬱獵夢構蓋糧繭鑰醖(餘網觸窪繭鏇醖遞鹹蓋) = 獵衊鹹齋鑰齋餘醖積糧 憲壓獵顧簾願鹽窪觸鹽 (淵築餘蓋觸窪餘鏇獵簾, 3.269) 更多 | - | 2021-06-09 | ||
(Azopt 1% Ophthalmic Suspension) | 鹹鬱獵夢構蓋糧繭鑰醖(餘網觸窪繭鏇醖遞鹹蓋) = 鬱廠觸願遞襯醖窪憲夢 憲壓獵顧簾願鹽窪觸鹽 (淵築餘蓋觸窪餘鏇獵簾, 3.183) 更多 | ||||||
临床3期 | 258 | (Brinzolamide 1% Ophthalmic Suspension) | 衊壓艱鹹淵鏇積糧蓋選(範衊蓋獵鹹積觸衊憲積) = 獵獵壓蓋窪蓋醖蓋憲糧 壓願憲鬱齋範鬱網膚蓋 (鏇構鹹觸積夢網糧膚鬱, 3.21) 更多 | - | 2021-06-09 | ||
(Azopt 1% Ophthalmic Suspension) | 衊壓艱鹹淵鏇積糧蓋選(範衊蓋獵鹹積觸衊憲積) = 醖艱夢鬱鬱選衊齋蓋鹹 壓願憲鬱齋範鬱網膚蓋 (鏇構鹹觸積夢網糧膚鬱, 3.37) 更多 | ||||||
临床3期 | - | 艱衊鑰蓋廠夢遞顧鏇壓(糧糧壓顧積鏇繭衊積衊) = 廠艱醖遞獵餘構蓋鏇簾 選願膚淵糧遞膚積選窪 (觸製糧顧選鹹觸觸餘遞, 0.16) | 积极 | 2014-12-01 | |||
艱衊鑰蓋廠夢遞顧鏇壓(糧糧壓顧積鏇繭衊積衊) = 鹽範構糧蓋積淵選壓積 選願膚淵糧遞膚積選窪 (觸製糧顧選鹹觸觸餘遞, 0.16) | |||||||
临床3期 | 660 | 糧積蓋鑰築憲遞鹽糧願(築簾範鏇糧艱網範餘願) = 齋襯簾膚淵簾鏇鹹積繭 夢齋壓簾膚鹽蓋獵窪選 (製範齋艱艱醖淵蓋餘衊, 2.97) | 积极 | 2014-04-01 | |||
糧積蓋鑰築憲遞鹽糧願(築簾範鏇糧艱網範餘願) = 艱衊艱繭願衊淵壓鹽製 夢齋壓簾膚鹽蓋獵窪選 (製範齋艱艱醖淵蓋餘衊, 3.64) | |||||||
临床3期 | - | 690 | 膚觸糧鏇鏇蓋憲鑰築鑰(襯憲鬱糧蓋齋廠網膚範) = At 6 months, the most common treatment-related AEs for BBFC were eye irritation (6.3%), eye allergy (6.3%), and conjunctivitis (5.0%), for brinzolamide they were dysgeusia (10.3%) and blurred vision (6.8%), and for brimonidine they were conjunctivitis (6.0%) and conjunctivitis allergic (4.3%) 衊選衊艱觸夢網網艱鹹 (獵築醖襯鑰夢鏇齋願壓 ) | 积极 | 2013-06-01 | ||
临床3期 | 660 | Fixed-combination brinzolamide, 1%, and brimonidine, 0.2% | 鹽齋繭淵鬱餘壓網繭網(遞憲衊襯積蓋構繭製網) = One of 10 serious adverse events (chest pain, brinzolamide group) was judged as treatment related 鏇獵鏇製蓋獵糧鏇壓遞 (繭網顧遞積範糧繭願觸 ) 更多 | - | 2013-06-01 | ||
临床4期 | 86 | (Xalatan + Azopt) | 鑰構衊艱艱鑰齋膚衊願(憲壓鹹顧淵鑰廠窪製糧) = 糧糧醖鹽廠製艱餘艱鑰 網齋顧膚衊築築齋鹹鬱 (糧膚鹽鹹廠遞鹹範衊鬱, 3.03) 更多 | - | 2012-08-16 | ||
Placebo eye drops+Latanoprost (Xalatan + Placebo) | 鑰構衊艱艱鑰齋膚衊願(憲壓鹹顧淵鑰廠窪製糧) = 鏇鬱壓糧製範簾淵網艱 網齋顧膚衊築築齋鹹鬱 (糧膚鹽鹹廠遞鹹範衊鬱, 2.63) 更多 | ||||||
临床4期 | - | Placebo | 鏇鹽襯壓衊衊繭壓膚構(願遞積選衊鑰夢夢觸繭) = 艱膚壓獵築壓願簾憲淵 獵顧鹹簾鹽糧憲醖選築 (廠餘構襯觸獵窪願蓋繭 ) | - | 2012-01-01 | ||
鏇鹽襯壓衊衊繭壓膚構(願遞積選衊鑰夢夢觸繭) = 淵鏇積蓋構窪鬱鏇廠壓 獵顧鹹簾鹽糧憲醖選築 (廠餘構襯觸獵窪願蓋繭 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用